Series B · Biotech · Ghent, Belgium · Founded 2020 · 40–50 employees
MRM Health is a clinical-stage biopharmaceutical company developing microbiome-based Live Biotherapeutic Products (LBPs) for chronic inflammatory diseases and immune-oncology, founded in 2020 as a spin-off from VIB and MRM Technologies in Ghent, Belgium. Its proprietary CORAL® platform enables the rational design and GMP-compliant co-fermentation manufacturing of multi-strain microbial consortia as a single drug substance, addressing a key industry bottleneck. The lead program MH002 — the most advanced rationally-designed LBP for inflammatory bowel diseases — has demonstrated positive Phase 2a results in both ulcerative colitis and the orphan indication pouchitis, and has received FDA IND clearance for a Phase 2b trial. In September 2025, the company closed a €55 million Series B round led by Biocodex, with participation from ATHOS, BNP Paribas Fortis Private Equity, SFPIM, Ackermans & van Haaren, OMX Europe Venture Fund, Qbic II, and VIB, alongside a strategic non-dilutive manufacturing partnership with Biocodex.
No open roles listed right now.